SARS-CoV-2 recombinant Spike (SCoV2-rS) glycoprotein full-length trimeric ectodomain and mutant variants of SCoV2-S
SARS-CoV-2 recombinant Spike (SCoV2-rS) glycoprotein full-length ectodomain expressed as secreted trimeric protein in mammalian cells. It was purified from culture medium under native (non-denaturing) conditions using convenient chromatographic techniques. Six different products of initial sequence (Wuhan) SCoV2-rS protein are available:
- 20-S2S-TCg-G: from mammalian CHO cells, in glycerol stock. (Approved for IVD use, CE mark)
- 20-S2S-TCg-F: from mammalian CHO cells, frozen.
- 20-S2S-TCg-L: from mammalian CHO cells, lyophilized.
- 21-S2S-TCg-F/B1: biotinylated SCoV2-rS glycoprotein trimeric ectodomain from mammalian CHO cells, frozen.
- 20-S2S-THs-G: from mammalian HEK293 cells, in glycerol stock.
- 20-S2S-THs-F: from mammalian HEK293 cells, frozen.
Note: The same protein from different cell lines is not identical in respect of post-translational modifications including glycosylation. Protein from CHO cells is more uniformly glycosylated and to a lesser extent than analogous product from HEK293 cells. Nevertheless, Spike glycoproteins secreted from either CHO or HEK cells show similar results in ELISA with COVID-19 positive and negative human sera.
Also, main Spike protein mutants (alpha, beta, delta, omicron, etc. variants) were synthesized in a form of the full-length trimeric proteins in CHO cells and purified in similar way as the initial SCoV2-rS protein sequence variant. Formulations of five mutants in either PBS (frozen) or glycerol stocks are available:
- 21-S2SUK1-TCg-F: SARS-CoV-2 Spike glycoprotein Alpha (B.1.1.7) variant trimeric ectodomain from mammalian CHO cells, frozen.
- 21-S2SUK1-TCg-G: SARS-CoV-2 Spike glycoprotein Alpha (B.1.1.7) variant trimeric ectodomain from mammalian CHO cells, in glycerol stock.
- 21-S2SSA1-TCg-F: SARS-CoV-2 Spike glycoprotein Beta (B.1.351) variant trimeric ectodomain from mammalian CHO cells, frozen.
- 21-S2SSA1-TCg-G: SARS-CoV-2 Spike glycoprotein Beta (B.1.351) variant trimeric ectodomain from mammalian CHO cells, in glycerol stock.
- 21-S2SIN1-TCg-F: SARS-CoV-2 Spike glycoprotein Indian-Kappa (B.1.617.1) variant trimeric ectodomain from mammalian CHO cells, frozen.
- 21-S2SIN1-TCg-G: SARS-CoV-2 Spike glycoprotein Indian-Kappa (B.1.617.1) variant trimeric ectodomain from mammalian CHO cells, in glycerol stock.